Lumos Diagnostics CEO Doug Ward joined Steve Darling from Proactive to discuss the company’s recent achievement of CLIA ...

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter Lumos Diagnostics Holdings Ltd. ( (AU:LDX)) has issued an announcement. Lumos ...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has secured $20 million in a strongly supported institutional placement, with the fresh capital to be used to scale manufacturing and commercial ...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) has used its March quarter update to underline a period of operational and strategic transition, as the company positions itself for expanded ...

Lumos Diagnostics Holdings Ltd (ASX:LDX, OTC:LDXHF) will host a virtual investor briefing on Thursday, June 11, at 10:30am AEST to provide an update on the US commercialisation of FebriDx® following ...

SARASOTA, Fla.--(BUSINESS WIRE)--RPS Diagnostics, Inc. (RPS®) today announced an updated CE mark of its FebriDx® test, clearing the way for its immediate launch in the European Union and all countries ...

In a recent JAMA Network Open study, researchers explore whether a point-of-care immunoassay called FebriDx could differentiate between bacteria- and virus-induced immune responses during acute ...

Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks Lumos Diagnostics has initiated a ...

Lumos Diagnostics’ FebriDx to be used in Australian university study aimed at reducing unnecessary antibiotic prescribing for respiratory infections in primary care settings. FebrixDx, which is ...

First Australian study to use FebriDx rapid point-of-care test in a general practice primary care setting FebrixDx, which is designed to differentiate between bacterial and non-bacterial acute ...